BWXT Q2 Deep Dive: Government Operations and Nuclear Services Outpace, Guidance Raised

Aerospace and defense company BWX (NYSE:BWXT) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 12.1% year on year to $764 million. The company’s full-year revenue guidance of $3.1 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $1.02 per share was 28.7% above analysts’ consensus estimates.

Is now the time to buy BWXT? Find out in our full research report (it’s free).

StockStory’s Take

BWX’s second quarter saw a significant positive market reaction, driven by operational strength in its Government Operations segment and successful integration of recent acquisitions. Management attributed this outperformance to robust execution in special materials and the timing of material procurement, as well as higher backlog growth across both government and commercial markets. CEO Rex Geveden highlighted that “demand across the global security, clean energy and medical end markets is accelerating,” and pointed to a surge in new contract wins, particularly large-scale naval nuclear reactor agreements, as key contributors to the quarter’s strong results.

Looking ahead, BWX’s increased full-year guidance is anchored in a growing pipeline of government contracts, expanding commercial nuclear opportunities, and continued momentum in medical isotopes. Management believes that further investments in capacity and the recent Kinectrics acquisition will support mid-teens organic growth and enable the company to meet rising demand in both defense and civilian nuclear markets. CFO Michael Fitzgerald noted that capital expenditures will rise to expand infrastructure, and the company expects to benefit from a diverse mix of new projects, stating, “We see an abundance of high-quality business cases right now, and much competition for capital.”

Key Insights from Management’s Remarks

Management attributed the quarter’s results to strong execution in Government Operations, timely contract wins, and expanding opportunities in medical and commercial nuclear markets, with notable contribution from the Kinectrics acquisition.

• Government Operations momentum: Strong operational performance and contract pacing in Government Operations, especially within special materials and naval propulsion, were major contributors to the quarter. The segment benefited from a new $2.6 billion pricing agreement for naval nuclear reactor components, which will support submarine and aircraft carrier programs over the next eight years.

• Backlog and book-to-bill growth: Total backlog reached $6 billion, up 70% year over year, with organic book-to-bill at 2.2 for the quarter. Management credited robust federal demand and a growing pipeline in both government and commercial operations, including large new projects in the U.S. and Canada.

• Kinectrics acquisition impact: The recent acquisition of Kinectrics added approximately $240 million to backlog and broadened BWX’s capabilities in life-of-plant services, further strengthening its position in the nuclear infrastructure market.

• Medical isotope expansion: BWX Medical saw double-digit revenue growth, driven by demand for PET diagnostic products and TheraSphere, with management highlighting regulatory progress for new isotopes like deuterium-90 and lutetium-177 in partnership with Laurentis Energy Partners.

• Commercial power project timing: Organic commercial power revenue was down slightly due to the timing of outage and maintenance projects, but growth in components work—such as the BWRX-300 reactor pressure vessel—offset some declines. Management expects stronger results in the second half as field services activity normalizes.

Drivers of Future Performance

BWX’s outlook is driven by continued strength in government contracts, expanding commercial nuclear work, and ongoing investment in capacity and new technologies.

• Defense and government contract pipeline: Management sees ongoing demand for naval propulsion, special materials, and technical services, supported by recent multi-year agreements and new opportunities in microreactors and advanced nuclear fuels. The company expects these contracts to underpin mid-single-digit revenue growth in Government Operations.

• Commercial nuclear and medical growth: Rising global interest in nuclear power, especially in Canada and the U.S., along with robust demand for medical isotopes, is expected to drive mid-teens organic growth in Commercial Operations. The Kinectrics acquisition and new regulatory approvals for isotope production are seen as pivotal.

• Margin and investment dynamics: While margins in commercial operations are expected to improve in the second half due to higher field services activity, management cautioned that increased capital expenditures—especially for capacity expansion and defense fuel infrastructure—will continue. Risks include project timing variability and supply chain factors, though management stated that commodity price impacts have recently stabilized.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will focus on (1) further backlog growth from new government and commercial nuclear contracts, (2) the pace of medical isotope revenue expansion and regulatory milestones for new products, and (3) execution of capital projects, particularly the ramp-up of field services and integration of Kinectrics. Progress in microreactor programs and international market penetration will also be closely tracked.

BWX currently trades at $179.54, up from $154.45 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.